罗扰素水剂治疗慢性肝炎疗效观察  

Therapeutical Effect of Roferon-A on Chronic Hepatitis

作　　者：宋建新[1] 田德英[1] 齐俊英[1] 魏镜龙[1] 

机构地区：[1]同济医科大学附属同济医院传染科,武汉430030

出　　处：《中西医结合肝病杂志》1999年第6期14-16,共3页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

摘　　要：目的：观察罗扰不剂治疗慢性乙型和丙型肝炎的疗效。方法：常规治疗组以罗扰素水剂３×１０＾６Ｕ，隔日１次，持续３个月；调整治疗组以罗扰素水剂４．５×１０＾６Ｕ，隔日１次，持续３～６个月；于治疗前、中、结果时及结束后３～６个月时检测ＨＣＶ、ＨＢＶ感染标志物及肝功能，并定量检测ＨＣＶ－ＲＮＡ、ＨＢＶ－ＤＮＡ及扰素抗体。结果：常规治疗组ＨＣＶ－ＲＮＡ转阴率为５０％，ＨＢｅＡｇ和ＨＢＶ－ＤＮＡ转阴率为４６．Aim: To evaluate the clinical effect of Roferon-A in the treatment of patients with hepatitis B and C. Method: Group 1 : 44 patients were given only Roferon-A 3×106U every two days for 3 months. Group 2:some patients with no effect in Group 1 were given Roferon-A 4. 5×106U every two days for another 3 to 6 months. HCV-Ab. HBV markers and ALT were detected before, during and at the end of the treatment and 3 to 6 months after the treatment. And at the same time the concentration of HCV-RNA. HBV-DNA in serum and antibody to Roferon-A were detected quantitatively. Results: In Group 1. HCV-RNA in 50% patients with hepatitis C became negative. HBeAg and HBV-DNA in 46. 2% patients with hepatitis B became negative. And the copies of HCV-RNA and HBV-DNA and the level of antibody to Roferon-A were negatively correlated with the effect of Roferon-A. Conclusion: The results showed that Ro-feron-A's eliminating rates of HCV-RNA、 HBV-DNA and the remission of ALT were close to that of Roferon. and were in dose-dependent manner.

关 键 词：干扰素 乙型肝炎 丙型肝炎 罗扰素水剂 药物疗法 

分 类 号：R512.605[医药卫生—内科学] R978.7[医药卫生—临床医学]